Real-World Studies
Real-World Comparison of Dual Checkpoint Blockade and Immunotherapy Plus TKIs in Metastatic RCC
Ohba et alCancer Medicine
In routine clinical practice, first-line combination therapy for metastatic renal cell carcinoma (mRCC) commonly incorporates either dual immune checkpoint blockade (ICI + ICI) or an ICI paired with a vascular endothelial growth factor receptor tyrosine kinase inhibitor (ICI + TKI). A retrospective multicenter cohort study evaluated 311 patients with International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate- or poor-risk metastatic RCC treated with first-line ICI-based combinations between 2018 and 2023. Investigators employed inverse probability of treatment weighting (IPTW) to minimize baseline imbalances across treatment groups.
Following IPTW adjustment, ICI plus TKI therapy was associated with a trend toward longer progression-free survival (PFS) compared with dual checkpoint blockade (median 28.7 vs. 16.6 months, HR 0.69, p = 0.050). Subgroup analyses revealed that this PFS advantage was more pronounced among intermediate-risk patients and those without central nervous system or bone metastases.
However, this early disease control advantage did not translate into a significant difference in extended oncologic outcomes. Overall survival was nearly identical between the ICI + TKI and ICI + ICI cohorts (median 57.4 vs. 57.0 months, HR 1.01, p = 0.965). Similarly, no statistically significant differences emerged regarding second progression-free survival (median 46.6 vs. 35.5 months, HR 0.84, p = 0.436), objective response rate (56.5% vs. 52.2%, p = 0.473), or duration of response (median 54.6 vs. 44.9 months, HR 0.83, p = 0.502). Safety profiles were comparable, with similar rates of grade ≥ 3 adverse events reported across both treatment strategies.
The authors noted that despite IPTW adjustment, the retrospective design introduces the potential for residual confounding. Clinicians should weigh individualized therapeutic priorities—such as rapid initial tumor control with TKI-based regimens versus durable immune-mediated disease control with dual checkpoint inhibition—when selecting frontline regimens for intermediate- and poor-risk mRCC.
Key Takeaways
- First-line immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor (TKI) therapy demonstrated a trend toward improved progression-free survival over dual ICI blockade (median 28.7 vs. 16.6 months; HR 0.69, p = 0.050), with pronounced benefit observed in intermediate-risk disease and in patients without central nervous system or bone metastases.
- Long-term survival outcomes showed no statistically significant differences between ICI plus TKI and dual ICI regimens for overall survival (median 57.4 vs. 57.0 months; HR 1.01, p = 0.965), second progression-free survival (median 46.6 vs. 35.5 months; HR 0.84, p = 0.436), or objective response rate (56.5% vs. 52.2%, p = 0.473).
- The incidence of grade ≥ 3 adverse events did not differ significantly between dual ICI therapy and ICI plus TKI combinations.
Read the original sourceCancer Medicine
